Version 1
: Received: 26 September 2023 / Approved: 27 September 2023 / Online: 29 September 2023 (07:50:01 CEST)
How to cite:
Talanki, A.; Bajaj, N.; Trehan, T.; Sathish, T. Incidence, Risk and Clinical Course of New-Onset Diabetes after COVID-19: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies. Preprints2023, 2023092048. https://doi.org/10.20944/preprints202309.2048.v1
Talanki, A.; Bajaj, N.; Trehan, T.; Sathish, T. Incidence, Risk and Clinical Course of New-Onset Diabetes after COVID-19: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies. Preprints 2023, 2023092048. https://doi.org/10.20944/preprints202309.2048.v1
Talanki, A.; Bajaj, N.; Trehan, T.; Sathish, T. Incidence, Risk and Clinical Course of New-Onset Diabetes after COVID-19: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies. Preprints2023, 2023092048. https://doi.org/10.20944/preprints202309.2048.v1
APA Style
Talanki, A., Bajaj, N., Trehan, T., & Sathish, T. (2023). Incidence, Risk and Clinical Course of New-Onset Diabetes after COVID-19: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies. Preprints. https://doi.org/10.20944/preprints202309.2048.v1
Chicago/Turabian Style
Talanki, A., Twinkle Trehan and Thirunavukkarasu Sathish. 2023 "Incidence, Risk and Clinical Course of New-Onset Diabetes after COVID-19: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies" Preprints. https://doi.org/10.20944/preprints202309.2048.v1
Abstract
Coronavirus disease 2019 (COVID-19), an infectious disease pandemic, affected millions of people globally, resulting in high morbidity and mortality. Causing further concern, significant proportions of COVID-19 survivors suffer from the lingering health effects of severe acute respiratory syndrome virus 2 (SARS-CoV-2), the pathogen that causes COVID-19. One of the diseases manifesting as a post-acute sequela of COVID-19 is new-onset diabetes. This systematic review and meta-analysis will perform a comprehensive and systematic literature search to estimate the burden of new-onset diabetes after COVID-19. Specifically, this study will estimate the magnitude of the incidence, risk, and population-attributable fraction of new-onset diabetes. The study will also explore and summarize the data on the natural history or clinical course of the new-onset diabetes cases. Five bibliographic databases, including PubMed, MEDLINE, Embase, Scopus, and Web of Science, will be searched for eligible studies. The World Health Organization COVID-19 Research Database, preprint servers, and conference abstracts will also be searched. Cohort studies of COVID-19 patients of all ages providing data on new cases of diabetes in the post-acute phase of the illness will be included. The comparators to estimate the pooled risk ratio will be those with no diagnosis of COVID-19 or those infected with other respiratory tract infections. The findings of this study will likely inform clinical practice, public health guidelines, and policies for early detection and treatment of new-onset diabetes cases in the long-COVID phase. This protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO: No.CRD42020200432).
Keywords
COVID-19; SARS-CoV-2; diabetes; new-onset diabetes; long-COVID; postacute sequelae of SARS-CoV-2
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
